Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges.

MLA

Sawyer, Tomi K., et al. “Macrocyclic α Helical Peptide Therapeutic Modality: A Perspective of Learnings and Challenges.” Bioorganic & Medicinal Chemistry, vol. 26, no. 10, June 2018, pp. 2807–15. EBSCOhost, https://doi.org/10.1016/j.bmc.2018.03.008.

APA

Sawyer, T. K., Partridge, A. W., Kaan, H. Y. K., Juang, Y.-C., Lim, S., Johannes, C., Yuen, T. Y., Verma, C., Kannan, S., Aronica, P., Tan, Y. S., Sherborne, B., Ha, S., Hochman, J., Chen, S., Surdi, L., Peier, A., Sauvagnat, B., Dandliker, P. J., … Lane, D. P. (2018). Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges. Bioorganic & Medicinal Chemistry, 26(10), 2807–2815. https://doi.org/10.1016/j.bmc.2018.03.008

Chicago

Sawyer, Tomi K, Anthony W Partridge, Hung Yi Kristal Kaan, Yu-Chi Juang, Shuhui Lim, Charles Johannes, Tsz Ying Yuen, et al. 2018. “Macrocyclic α Helical Peptide Therapeutic Modality: A Perspective of Learnings and Challenges.” Bioorganic & Medicinal Chemistry 26 (10): 2807–15. doi:10.1016/j.bmc.2018.03.008.